Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
hADME and Absolute Bioavailability Trial of BI 1584862 in Healthy Men
NCT07336758Phase 1Completed
- Sponsor
- Boehringer Ingelheim
- Start
- Jan 2026
- Primary completion
- Mar 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of BI 1584862, sponsored by Boehringer Ingelheim. Primary endpoints: Fraction excreted in urine, Fraction excreted in faeces and 2 more. Started Jan 2026; status: completed.
02
Drugs
BI 1584862
Beyond the preview
Go deeper on NCT07336758.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07336758.